About ImmunoACT
ImmunoACT is a company based in Mumbai (India) founded in 2018 by Atharva Karulkar and Rahul Purwar. ImmunoACT has raised $15.87 million across 5 funding rounds from investors including Laurus Labs and SINE. The company has 69 employees as of April 07, 2024. ImmunoACT offers products and services including NexCAR19. ImmunoACT operates in a competitive market with competitors including Adicet Bio, Orca Bio, Ossium Health, Nordic Nanovector and Kiadis Pharma, among others.
- Headquarter Mumbai, India
- Employees 69 as on 07 Apr, 2024
- Founders Atharva Karulkar, Rahul Purwar
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immunoadoptive Cell Therapy Private Limited
- Date of Incorporation 08 Oct, 2018
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$1.29 M (USD)1454.31as on Mar 31, 2024
-
Net Profit
-$1.77 M (USD)-46.6as on Mar 31, 2024
-
EBITDA
-$1.33 M (USD)-92.92as on Mar 31, 2024
-
Total Equity Funding
$15.87 M (USD)
in 5 rounds
-
Latest Funding Round
$9.67 M (USD), Series B
May 31, 2023
-
Investors
Laurus Labs
& 1 more
-
Employee Count
69
as on Apr 07, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ImmunoACT
ImmunoACT offers a comprehensive portfolio of products and services, including NexCAR19.
Modifies T-cells to target and eliminate cancer cells in patients.
People of ImmunoACT
Unlock access to complete
Unlock access to complete
Funding Insights of ImmunoACT
ImmunoACT has successfully raised a total of $15.87M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $9.67 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ImmunoACT
ImmunoACT has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Laurus Labs and SINE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector-agnostic startups are accelerated by SINE, backed by IIT Bombay.
|
Locked | Locked | Locked | |
|
Pharmaceutical and biotechnology company
|
Locked | Locked | Locked |
Investor details for ImmunoACT
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ImmunoACT
Investment portfolio details for ImmunoACT
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ImmunoACT
Detailed financials for ImmunoACT
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immunoact Comparisons
Peer comparison for ImmunoACT
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ImmunoACT
ImmunoACT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, Orca Bio, Ossium Health, Nordic Nanovector and Kiadis Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immune cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Ossium Health is focused on bioengineering for improved health.
|
|
| Locked | Locked | Locked |
Antibody radionuclide conjugates are developed for haematological cancers.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for hematopoietic stem cell transplants are developed.
|
Detailed competitors of ImmunoACT
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunoact
Complete news archive for ImmunoACT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImmunoACT
ImmunoACT was founded in 2018 and raised its 1st funding round 1 year after it was founded.
ImmunoACT is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
ImmunoACT is a funded company, having raised a total of $15.87M across 5 funding rounds to date.
As of Apr 07, 2024, the latest employee count at ImmunoACT is 69.
Annual revenue of ImmunoACT is $1.29M as on Mar 31, 2024.
ImmunoACT was established in 2018 in Mumbai, India, within the biotechnology sector. Cell therapies targeting cancer are developed using a patented CAR-T platform that incorporates a design algorithm for pipeline candidates. These include Actalycabtagene autoleucel for B-lymphoid malignancies, HCAR2 for multiple myeloma, and HCAR3 for glioblastoma multiforme and neuroblastoma. Focus is placed on immuno-oncology advancements.
ImmunoACT's top competitors include Orca Bio, Ossium Health and Adicet Bio.
ImmunoACT offers NexCAR19.
ImmunoACT has 2 investors. Key investors include Laurus Labs, and SINE.
The valuation of ImmunoACT is $10.81M as of Oct 2021.